Our Journey
We are transforming the advanced therapies industry.
Built to Push Advanced Therapies Forward
A new era of transformative medicine requires a new approach. Traditional models with fragmented capabilities, siloed expertise, infrastructure built for yesterday’s therapies aren’t equipped to deliver on the promise of what advanced therapies have become.
ElevateBio was founded in 2017 to build something different: a company that concentrates proprietary technologies, flexible manufacturing, and deep scientific expertise under one roof so the field can move faster than any single organization could on its own. Our team is advancing the science, refining the manufacturing processes, and solving the technical challenges that stand between breakthrough research and therapies that reach patients.
Together, we are changing the future of medicine.
// Our Journey
Our Journey
Mar
2026
Demonstrated an Automated Cell Therapy Manufacturing Platform
Partnered with Sartorius to develop an automated, closed cell therapy platform with functional potency and manufacturing consistency to lower manufacturing risk, timelines, and costs
Dec
2025
Achieve 98% Manufacturing Batch Success Rate
Achieved a 98% manufacturing batch success rate across cell therapy, viral vector, and mRNA batches, exceeding industry standards and reducing costs and development timelines for partners
Aug
2025
Demonstrate Compliant, Scalable, and Commercial-Level Manufacturing Capabilities
Became the first genetic medicines manufacturer to achieve multi-modality Initiative for Certification of Manufacturing Capabilities (ICMC) certification across viral, non-viral, and cell therapy manufacturing – the most rigorous third-party manufacturing evaluation in the industry
May
2025
Apply Generative AI to Expand CRISPR Discovery
Established a multi-year collaboration with Amazon Web Services to leverage generative AI to expand and accelerate CRISPR discovery, design, and drug development for thousands of complex monogenic and polygenic diseases
Oct
2024
Demonstrate Non-Viral Delivery Capabilities with Lipid Nanoparticle Platform
Demonstrated successful in vivo delivery of ElevateBio gene editing systems with its proprietary LNP platform to enable nuclease editing in the liver, reinforcing our mission to offer comprehensive solutions to innovators across the industry
May
2024
Bolster Gene Editing Technology Stack with New U.S. Patents
Receive multiple patents from the United States Patent and Trademark Office covering multiple enzymes, underscoring the novelty of our gene editing systems to make a broad spectrum of DNA edits and accelerate our partners’ development of therapies
May
2023
Partner with Novo Nordisk on Gene Editing R&D
Established a multi-target R&D collaboration with Novo Nordisk worth up to ~$1.9B to discover and develop gene editing therapies for rare and cardiometabolic diseases
May
2023
Close Series D $401M Financing Round
Closed a $401 million financing round – the largest biotech venture deal of the year – bringing total capital raised to ~$1.3 billion and reflecting strong investor confidence in the company's mission.
Nov
2022
Establish Manufacturing Blueprint for Base-Edited Therapies
Manufactured a leading base editing therapy for rare disease, establishing the manufacturing blueprint and commercial scale-up pathway for a novel class of gene-edited therapy.
Aug
2022
Expand Our Footprint in Partnership with the University of Pittsburgh
Partnered with the University of Pittsburgh to build a biomanufacturing facility in Pittsburgh, made possible by a $100M grant from the Richard King Mellon Foundation – the largest grant in the foundation’s history
Oct
2021
Added Industry-Leading Gene Editing Technology
Acquired Life Edit Therapeutics, expanding its technology stack with one of the world’s largest toolboxes of gene editing technologies that provide flexible editing and unprecedented access to the genome
Jan
2020
Open First Purpose-Built Biomanufacturing Facility
Opens our flagship biomanufacturing facility in Waltham, MA, designed and built from the ground up to support advanced therapies
May
2019
Launch to Power Cell and Gene Therapy
ElevateBio officially launched to power the cell and gene therapy industry.
2017
Our Foundation
Our founders ask the question: what could revolutionize medicine in the next 50 years? ElevateBio was formed.
Partner with ElevateBio®
Wherever you are in your advanced therapy product lifecycle, we can strengthen and accelerate your development journey with our enabling technologies and unmatched process development and manufacturing capabilities.
// Work with us
